Immune Response News and Research

RSS

Personalized cancer vaccines can be used to marshal powerful immune response

Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients' tumors, according to early data in a first-in-people clinical trial at Washington University School of Medicine in St. Louis.

6 Apr 2015

Simple test outperforms current standard test for early-stage prostate cancer

A test that costs less than a $1 and yields results in minutes has been shown in newly published studies to be more sensitive and more exact than the current standard test for early-stage prostate cancer.

6 Apr 2015

Thomas Jefferson University, Exosome Sciences team up to evaluate new liquid biopsy platform

Today, Thomas Jefferson University announces a partnership with Exosome Sciences Inc. to evaluate a novel liquid biopsy platform that might offer clinicians new and actionable information about a patient's cancer as the disease progresses and changes, via a simple blood test.

3 Apr 2015

Canada's VSV-EBOV Ebola vaccine proves safe, effective in Phase 1 clinical trial

The Honourable Rona Ambrose, Minister of Health, and Canada's Chief Public Health Officer, Dr. Gregory Taylor, today welcomed the news of promising trial outcomes of Canada's VSV-EBOV Ebola vaccine. The results of several studies and trials bring the world closer to ending this global outbreak through the provision of a commercially available vaccine.

2 Apr 2015

MD Anderson, NanoString Technologies collaborate to accelerate development of 'multi-omic' assays

The University of Texas MD Anderson Cancer Center and NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced a multi-year collaboration to accelerate the development and adoption of a new type of assay based on NanoString's nCounter Analysis System.

From NanoString Technologies 1 Apr 2015

Study provides insights into basis for cognitive dysfunction

Scientists at Columbia University's Mailman School of Public Health have identified a unique pattern of immune molecules in the cerebrospinal fluid of people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) that provides insights into the basis for cognitive dysfunction--frequently described by patients as "brain fog"--as well as new hope for improvements in diagnosis and treatment.

31 Mar 2015

CRT, BioInvent, and University of Southampton partner to develop new immunotherapy treatments for cancer

Cancer Research Technology, the commercialization and development arm of Cancer Research UK and BioInvent International today announce the start of a two-year research collaboration with leading antibody researchers at the University of Southampton.

30 Mar 2015

Experimental immunotherapy shows promise in women with stage III or IV ovarian cancer

Personalized medicine is getting closer to reality for women with late-stage ovarian cancer. An experimental immunotherapy is in the works that can target an individual woman's tumor and extend the time period between initial treatment and the cancer's return.

29 Mar 2015

New Ebola vaccine shows promise in first phase 1 clinical trial

Results from the first phase 1 trial of an Ebola vaccine based on the current (2014) strain of the virus are today published in The Lancet. Until now, all tested Ebola virus vaccines have been based on the virus strain from the Zaire outbreak in 1976. The results suggest that the new vaccine is safe, and provokes an immune response in recipients, although further long-term testing will be needed to establish whether it can protect against the Ebola virus.

27 Mar 2015

Aridis Pharmaceuticals begins Aerucin Phase 1 clinical study for treatment of acute pneumonia

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today the initiation of a Phase 1 clinical study of Aerucin, the Company's fully human IgG1 monoclonal antibody (mAb) against Pseudomonas aeruginosa bacteria, which is being developed as an adjunctive treatment for acute pneumonia.

26 Mar 2015

Metabolic imbalance can trigger respiratory diseases in early childhood

An imbalance in our metabolism can trigger inflammatory processes in the body and activate the immune system. In a recent study, published in the Journal of Allergy and Clinical Immunology, UFZ researchers have been able to show that this applies even to newborns and children under one year of age, and is correlated with the development of respiratory diseases in early childhood.

26 Mar 2015

Study: HBV exposure increases immune system maturation of infants

A Singapore led study has shown that Hepatitis B Virus Infection (HBV) exposure increases the immune system maturation of infants, which may give a better survival advantage to counteract bacterial infection during early life. These findings radically modify the way that HBV vertical infection of neonates (mother-to-child) is portrayed, and present a paradigm shift in the approach to treatment of patients with chronic hepatitis B.

26 Mar 2015

CMV-based vaccine provides long-lasting protective immunity against Ebola virus

A cytomegalovirus (CMV)-based vaccine provides long-lasting protective immunity against Ebola virus, and has potential for development as a disseminating vaccine strategy to prevent ebolavirus infection of wild African ape populations.

25 Mar 2015

Norovirus vaccine may be available in the future

A multivalent candidate vaccine elicits broad antibody responses to a range of norovirus strains, including strains not included in the vaccine or previously encountered by participants, according to a new study published this week in PLOS Medicine.

25 Mar 2015

Duke researchers develop new model to study why some HPV infections go away and others progress

For people infected with the human papilloma virus (HPV), the likelihood of clearing the infection and avoiding HPV-related cancer may depend less on the body's disease-fighting arsenal than has been generally assumed.

25 Mar 2015

Discovery opens door to possible new ways to break transmission cycle of schistosomiasis

Researchers at Oregon State University have discovered a group of genes in one species of snail that provide a natural resistance to the flatworm parasite that causes schistosomiasis, and opens the door to possible new drugs or ways to break the transmission cycle of this debilitating disease.

25 Mar 2015

Genetic flaws in bowel cancer may trigger immune response at site of tumours

Scientists have found that genetic changes in bowel tumours are linked to the way the body's immune system responds to the cancer, according to research published today (Monday) in the journal Oncoimmunology.

23 Mar 2015

Study reveals functional heterogeneity of CD4 T cells in immune systems

Utilizing a novel transgenic mouse model, Edward Usherwood, PhD of Dartmouth's Norris Cotton Cancer Center and collaborators found that CD4 T cells divide into two different populations that each has a different job. One type performs antiviral functions, and the other survives life in the host.

23 Mar 2015

New triple combination therapy shows promise in controlling advanced melanoma

Results of a new study by UCLA researchers has found that a groundbreaking new triple combination therapy shows promising signs of more effectively controlling advanced melanoma than previous BRAF + MEK inhibitor or BRAF inhibitor + immunotherapy combos alone, and with increased immune response and fewer side effects.

20 Mar 2015

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

Pharmacyclics, Inc. today announced that new pre-clinical and clinical data for ibrutinib (IMBRUVICA) will be highlighted at the 2015 American Association for Cancer Research Annual Meeting to be held April 18 – 22, 2015, in Philadelphia, PA.

19 Mar 2015

Immune Response News and Research

Personalized cancer vaccines can be used to marshal powerful immune response

Simple test outperforms current standard test for early-stage prostate cancer

Thomas Jefferson University, Exosome Sciences team up to evaluate new liquid biopsy platform

Canada's VSV-EBOV Ebola vaccine proves safe, effective in Phase 1 clinical trial

MD Anderson, NanoString Technologies collaborate to accelerate development of 'multi-omic' assays

Study provides insights into basis for cognitive dysfunction

CRT, BioInvent, and University of Southampton partner to develop new immunotherapy treatments for cancer

Experimental immunotherapy shows promise in women with stage III or IV ovarian cancer

New Ebola vaccine shows promise in first phase 1 clinical trial

Aridis Pharmaceuticals begins Aerucin Phase 1 clinical study for treatment of acute pneumonia

Metabolic imbalance can trigger respiratory diseases in early childhood

Study: HBV exposure increases immune system maturation of infants

CMV-based vaccine provides long-lasting protective immunity against Ebola virus

Norovirus vaccine may be available in the future

Duke researchers develop new model to study why some HPV infections go away and others progress

Discovery opens door to possible new ways to break transmission cycle of schistosomiasis

Genetic flaws in bowel cancer may trigger immune response at site of tumours

Study reveals functional heterogeneity of CD4 T cells in immune systems

New triple combination therapy shows promise in controlling advanced melanoma

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

Understanding the DNA Damage Response in Innate Immunity eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News